KOSPIBiotech & Pharma002720

Kukje Pharma

₩2,980▼ 0.33%2026-11-18 close
Market Cap
₩63.1B
Turnover
₩300M
Volume
110K
Shares out.
21.2M
PER
17.9×
PBR
0.6×
EPS
₩166
Dividend Yield
1.01%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩30 per share · Prices as of the 2026-11-18 close

01

Report overview

Eye-care growth, thinner profit cushion at Kukje Pharma

Kukje Pharma is growing revenue on the back of eye-care drugs, but its operating profit fell 29.8% year on year in the third quarter of 2026, and net profit attributable to controlling shareholders has declined for two consecutive quarters.

  1. 1

    Eye-care drugs are the growth engine. First-half 2026 eye-drop sales were about KRW 28.9 billion, up 29.1%, and their share of total sales rose to 31.3% (per press reports).

  2. 2

    Revenue has risen for three straight years from 2023 through 2025, reaching KRW 175.5 billion in 2025. Operating profit, however, fell 7.7% to KRW 6.18 billion in 2025.

  3. 3

    Operating profit in the third quarter of 2026 was KRW 1.34 billion, down 29.8% year on year, and net profit attributable to controlling shareholders was KRW 458 million, declining for two consecutive quarters.

  4. 4

    Over the last four quarters (Q4 2025 to Q3 2026), net profit attributable to controlling shareholders totaled KRW 3.55 billion, a small base that produces large swings from quarter to quarter.

  5. 5

    A KRW 55.52 billion investment at the Ansan plant aims to lift eye-drop capacity by 133%, so the burden of the investment and a recovery in margins are the two items to track together.

02

Business structure

Kukje Pharma, founded in 1959, is headquartered in Seongnam, Gyeonggi Province, and has built eye-care drugs into its core business. According to press reports, eye-drop sales rose from about KRW 34.7 billion in 2023 to KRW 39.6 billion in 2024 and KRW 45.5 billion in 2025.

First-half 2026 eye-drop sales were about KRW 28.9 billion, up 29.1% year on year, lifting their share of total sales to 31.3%. The flagship Queal eye drops reached about KRW 13.7 billion in the same period, up 22.8%, and the dry-eye treatment Leva Eye rose to about KRW 2.6 billion, up 24.4%.

Products outside eye care were comparatively weak, holding total sales growth to 6.7%. On the ethical drug side, the company attributed its 2024 return to operating profit to higher sales of antibiotics, cardiovascular drugs and cerebrovascular agents.

The sales structure shifted toward a contract sales organization (CSO) model for clinic-level sales, with headcount at 250 at the end of the third quarter of 2024, 35% below 384 in 2022.

Production is concentrated at the Ansan plant, where eye-drop output rose from about 123.08 million units in 2023 to 175.63 million units in 2025.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩45.6B₩1.9B4.2%
2025Q4₩43.3B-₩1.5B−3.6%
2026Q1₩44B₩2B4.5%
2026Q2₩48.3B₩2.1B4.4%
2026Q3₩47.9B₩1.3B2.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩126.6B₩5.3B₩3.6B4.2%4.8%84.4%
2023₩135.4B-₩2B-₩8.4B−1.5%−9.9%92.2%
2024₩156.5B₩6.7B₩5.2B4.3%5.8%84.9%
2025₩175.5B₩6.2B₩5.7B3.5%5.8%86.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 126.6 billion in 2022 to KRW 135.4 billion in 2023 (up 6.9% year on year), KRW 156.5 billion in 2024 (up 15.6%), and KRW 175.5 billion in 2025 (up 12.2%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022 to 2025 period.

Operating profit went from KRW 5.27 billion in 2022 to an operating loss of KRW 1.99 billion in 2023, returned to a profit of KRW 6.7 billion in 2024, and then fell 7.7% to KRW 6.18 billion in 2025. The operating margin moved from 4.2% in 2022 to -1.5% in 2023, 4.3% in 2024 and 3.5% in 2025.

Selling and administrative expenses, per an aggregator's consolidated tally, rose from KRW 75.8 billion in 2024 to KRW 87.5 billion in 2025, and press coverage pointed to higher commission fees.

Net profit attributable to controlling shareholders was KRW 3.56 billion in 2022, a net loss of KRW 8.42 billion in 2023, KRW 5.21 billion in 2024 and KRW 5.7 billion in 2025 (up 9.5%).

Quarterly revenue was KRW 45.6 billion in Q3 2025, KRW 43.3 billion in Q4 2025 (down 5.0% from the prior quarter), KRW 44 billion in Q1 2026, KRW 48.3 billion in Q2 2026 (up 9.9% quarter on quarter), and KRW 47.9 billion in Q3 2026 (down 0.8% quarter on quarter, up 5.0% year on year).

Operating profit was KRW 1.92 billion in Q3 2025, an operating loss of KRW 1.54 billion in Q4 2025, KRW 1.97 billion in Q1 2026, KRW 2.13 billion in Q2 2026, and KRW 1.34 billion in Q3 2026 (down 37.0% quarter on quarter and 29.8% year on year).

Net profit attributable to controlling shareholders peaked at KRW 2.15 billion in Q1 2026 and then fell to KRW 1.67 billion in Q2 and KRW 458 million in Q3, a decline over two consecutive quarters.

Operating cash flow was KRW 6.5 billion in 2022, KRW 3.58 billion in 2023, KRW 3.94 billion in 2024 and KRW 5.84 billion in 2025.

05

Industry analysis

The domestic pharmaceutical sector is split between revenue growth and uneven profitability. Based on preliminary figures compiled from Financial Supervisory Service data, the ten major pharmaceutical companies together posted third-quarter 2026 sales up 2.63% year on year and operating profit up 11.20%.

Excluding GC Biopharma, whose net profit rose sharply, the remaining companies' net profit was weak, according to one analysis.

Of 75 listed pharmaceutical and biotech companies, 45 reported an operating profit in the first half of 2026, with earnings concentrated in large biotech firms and high-margin companies, per press coverage.

Kukje Pharma's demand base is the ophthalmic treatment market, where eye-drop sales growth of 29.1% outpaced its total sales growth of 6.7% in the first half of 2026. Competitors in eye-care drugs are also reported to be expanding production capacity, and Kukje Pharma is responding with its own Ansan plant investment.

Some domestic peers are broadening into global new drug commercialization and CDMO work, a different model from Kukje Pharma's domestic generic-focused sales. Accounting changes for drug price refund reserves have also reduced reported sales at some companies, so comparisons of revenue depend on accounting basis.

06

Outlook

The most concrete company plan is the Ansan plant expansion. The company is investing KRW 55.52 billion to build a new eye-drop and solid-dosage production building and a product warehouse, with the program reported to run through 2029.

The investment is meant to raise eye-drop capacity by 133% and, through replacement of aging equipment, to improve production yields and manufacturing costs. The expansion could lift output and lower unit costs, but depreciation and financing costs may rise first during construction.

Eight biosimilar products sold jointly with Celltrion Pharm were reported in 2025 to be launching in sequence. The glaucoma candidate TFC003 was reported in 2025 to be in Phase 3, and a follow-on candidate, KJ-024-1, was described as preparing an IND filing after toxicity evaluation.

Operating profit fell to KRW 1.34 billion in the third quarter of 2026, so the next checkpoint is whether the plant investment and new launches translate into a margin recovery.

The alternative production arrangements for the product halt announced in September 2025 will show up in the revenue trend of later regular reports. The 2026 annual report is due by the end of March 2027 and will confirm full-year eye-drop sales and the operating margin.

07

Valuation

PER
17.9×
PBR
0.6×
ROE
3.6%
EPS
₩166
BPS
₩4,710
Dividend per share
₩30

The stock trades below book value, with the price-to-book ratio under 1x, which means a discount to net assets relative to the company's equity. The market may be pricing in a conservative view of how the equity base generates earnings.

The price-to-earnings ratio is sensitive to earnings size: net profit attributable to controlling shareholders totaled KRW 3.55 billion over the last four quarters, so a single quarter's change moves the multiple materially.

Because third-quarter 2026 profit declined, the multiple calculated on the last four quarters is higher than it would have been before that decline. Over several years the company moved from an operating loss in 2023 to a profit in 2024 and sustained profit through 2025, but the absolute earnings base remains small.

The sustainability of the profit recovery matters more than past share price levels. Dividend capacity tracks earnings size, so swings in profit pass directly into the room for payouts.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Eye-care growth engine

First-half 2026 eye-drop sales were about KRW 28.9 billion, up 29.1%, lifting their share of total sales to 31.3%. Queal and Leva Eye both grew, and eye-drop sales rose from about KRW 34.7 billion in 2023 to KRW 45.5 billion in 2025, per press reports. The revenue expansion case rests on this segment staying on its growth path.

Capacity expansion plan

The company plans to invest KRW 55.52 billion at the Ansan plant to raise eye-drop capacity by 133%. Replacing aging equipment is also meant to improve yields and unit costs. Eye-drop output rose 42.7% from 2023 to 2025, which supports reading the expansion as a response to demand growth.

Profit recovery and balance sheet

Operating profit moved from a KRW 1.99 billion loss in 2023 to KRW 6.7 billion in 2024. Operating cash flow rose to KRW 5.84 billion in 2025 from KRW 3.58 billion in 2023. The debt ratio fell from 92.2% in 2023 to 86.6% in 2025, with total equity at KRW 97.7 billion at the end of 2025.

09

Bear factors

Margin pressure and quarterly declines

Operating profit in the third quarter of 2026 was KRW 1.34 billion, down 29.8% year on year and 37.0% quarter on quarter. Net profit attributable to controlling shareholders fell from KRW 2.15 billion in Q1 2026 to KRW 458 million in Q3, declining for two consecutive quarters. Revenue grew, but the operating margin narrowed from 4.3% in 2024 to 3.5% in 2025.

Non-eye-care products and selling costs

Outside eye-care, products were comparatively weak in the first half of 2026, holding total sales growth to 6.7%. Press coverage reported that pharmaceutical segment sales rose in 2025 while segment operating profit fell. The shift to a CSO model increased commission fees and changed the selling cost structure.

Quality issue and investment burden

In September 2025 the company announced a halt to some drug production, with quality issues given as the reason. The KRW 55.52 billion Ansan expansion runs through 2029, and depreciation and financing costs may weigh on margins during construction.

10

Risk factors

Production and quality

The September 2025 halt in some drug production was reported as caused by quality problems. The company said it set up alternative production, but whether output normalized and how far the impact reached will appear in later regular-report revenue. Because eye care is the core, a production disruption could hit sales directly.

Capex and cash

The Ansan expansion involves KRW 55.52 billion, with the program running through 2029. Cash and cash equivalents were about KRW 9.1 billion at the end of Q1 2026, down from about KRW 10.7 billion at the end of 2025, per an aggregator's consolidated tally.

The investment is large relative to operating profit, so funding sources and financial headroom are items to track.

Product concentration and sales costs

Eye-care growth is carrying overall revenue, so demand shifts in a few products feed heavily into total sales. Press coverage linked higher commission fees from the CSO model to a lower operating margin. Competitors in the same segment are also expanding production capacity.

11

What to watch next

  1. Around February 2027 (expected)

    Preliminary Q4 and full-year 2026 results. The checkpoint is whether profit recovered after the Q4 2025 operating loss and how the full-year operating margin compares with 3.5% in 2025.

  2. End of March 2027

    Filing of the 2026 annual report. Full-year revenue, operating profit, net profit attributable to controlling shareholders and the eye-drop share are fixed in the regular report.

  3. Around mid-April 2027 (expected)

    Preliminary Q1 2027 results. The checkpoints are whether the operating profit decline extends another quarter and whether eye-drop growth holds near the 29.1% pace of the first half of 2026.

  4. Through 2029

    Progress of the Ansan eye-drop expansion. The next checkpoint is whether the 133% capacity increase and yield and cost gains show up in revenue and margins.

12

Overall view

Kukje Pharma's eye-care sales rose 29.1% in the first half of 2026, lifting their share of total sales to 31.3% and making eye care the clear growth axis. On a disclosed basis, revenue rose for three consecutive years from 2023 through 2025, reaching KRW 175.5 billion in 2025.

Operating profit, however, fell 7.7% to KRW 6.18 billion in 2025, and in the third quarter of 2026 it was KRW 1.34 billion, down 29.8% year on year. Net profit attributable to controlling shareholders has declined for two consecutive quarters since its Q1 2026 peak, leaving a four-quarter total of KRW 3.55 billion.

Strengths include eye-care growth, the capacity expansion and a profit return since 2024. Weaknesses include margin pressure, weak non-eye-care products, the production quality issue and the cost of the expansion.

The price-to-book ratio below 1x is a fact about how the market values the equity base relative to earnings. The next checkpoints are the preliminary Q4 2026 results, the 2026 annual report due by the end of March 2027, and progress on the Ansan expansion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. topdaily.kr
  2. thevc.kr
  3. medipana.com
  4. comp.fnguide.com
  5. dailypharm.com
  6. goinsider.kr
  7. bloter.net
  8. medipana.com
  9. medipana.com
  10. m.sedaily.com
  11. bosa.co.kr
  12. eugenefn.com
  13. catch.co.kr
  14. accidentalorder.com
  15. pharmnews.com
  16. medipharmhealth.co.kr
  17. bbn.kiwoom.com
  18. comp.fnguide.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis